Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of three medications used to treat inflammatory conditions while preventing gastrointestinal complications. Meloxicam is a selective COX-2 inhibitor NSAID used for pain and inflammation in conditions like rheumatoid arthritis. Misoprostol is a synthetic prostaglandin that protects the gastric mucosa. Rebamipide is a mucosal protective agent that enhances gastric defense mechanisms through multiple pathways including COX-2 stimulation, free radical scavenging, and suppression of neutrophil activity. This combination aims to provide anti-inflammatory benefits while minimizing the risk of NSAID-induced gastrointestinal injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meloxicam + misoprostol + rebamipide.